DiamiR LLC (DiamiR) is a medical device company. It carries out the development and commercialization of technology based on the analysis of brain-enriched microRNA biomarkers in blood plasma to be used for screening, and early and differential diagnosis. The company also offers microRNAs which are a class of small non-coding regulatory RNA molecules which modulate target gene expression and protein production. DiamiR offers a universal screening test comprised of organ-enriched microRNA panels which could be used to detect the presence of pathology in a particular organ or organ system. The company develops programs for neurodegenerative diseases, healthy aging and neurodevelopment disease. It has collaborations with academia, medical centers, disease foundations and industry. DiamiR is headquartered in Monmouth Junction, New Jersey, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company DiamiR LLC
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- DiamiR LLC Company Overview
- DiamiR LLC Company Snapshot
- DiamiR LLC Pipeline Products and Ongoing Clinical Trials Overview
- DiamiR LLC - Pipeline Analysis Overview
- DiamiR LLC - Key Facts
- DiamiR LLC - Major Products and Services
- DiamiR LLC Pipeline Products by Development Stage
- DiamiR LLC Pipeline Products Overview
- CogniMIR
- CogniMIR Product Overview
- Diagnostic Assay - Amyotrophic Lateral Sclerosis
- Diagnostic Assay - Amyotrophic Lateral Sclerosis Product Overview
- Diagnostic Assay - Frontotemporal Degeneration
- Diagnostic Assay - Frontotemporal Degeneration Product Overview
- Diagnostic Assay - Parkinson's Disease
- Diagnostic Assay - Parkinson's Disease Product Overview
- Diagnostic Assay - Rett Syndrome
- Diagnostic Assay - Rett Syndrome Product Overview
- Mdx Test - Brain Aging
- Mdx Test - Brain Aging Product Overview
- Mdx Test - MCI-AD Progression
- Mdx Test - MCI-AD Progression Product Overview
- Mdx Test - Mild Cognitive Impairment
- Mdx Test - Mild Cognitive Impairment Product Overview
- Universal Screening Test
- Universal Screening Test Product Overview
- DiamiR LLC - Key Competitors
- DiamiR LLC - Key Employees
- DiamiR LLC - Locations And Subsidiaries
- Head Office
- Recent Developments
- DiamiR LLC, Recent Developments
- Oct 02, 2023: DiamiR Biosciences Announces Poster Presentation at 52nd Annual Meeting of Child Neurology Society
- Jul 05, 2023: DiamiR Biosciences Partners with JADBio to Utilize Machine Learning in Assay Development
- Jun 28, 2023: DiamiR Biosciences Announces Publication of Analytical Validation Data for its microRNA Testing Platform
- Nov 28, 2022: DiamiR Biosciences Announces Poster Presentation at the Clinical Trials on Alzheimers Disease 2022 Annual Meeting
- Feb 11, 2021: DiamiR receives USPTO notice of allowance for key patent covering the use of microRNA biomarkers from bodily fluids for diagnosis and monitoring of Rett Syndrome and other neurodevelopmental diseases
- Oct 05, 2020: DiamiR announces oral presentation at 21st International Conference on Alzheimer's Drug Discovery
- Oct 01, 2020: DiamiR awarded $3.86M in two grants from the NIH
- May 27, 2020: DiamiR receives USPTO notice of allowance for key patent covering the use of circulating brain-enriched microRNA biomarkers for monitoring of brain aging; provides update on its patent portfolio
- Nov 20, 2019: DiamiR receives award from Alzheimer's Drug Discovery Foundation to accelerate development of microRNA biomarkers for Alzheimer's Disease
- Sep 16, 2019: DiamiR announces additional $345,000 funding from the NIH for Development of CogniMIR
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- DiamiR LLC Pipeline Products and Ongoing Clinical Trials Overview
- DiamiR LLC Pipeline Products by Equipment Type
- DiamiR LLC Pipeline Products by Indication
- DiamiR LLC, Key Facts
- DiamiR LLC, Major Products and Services
- DiamiR LLC Number of Pipeline Products by Development Stage
- DiamiR LLC Pipeline Products Summary by Development Stage
- CogniMIR - Product Status
- CogniMIR - Product Description
- Diagnostic Assay - Amyotrophic Lateral Sclerosis - Product Status
- Diagnostic Assay - Amyotrophic Lateral Sclerosis - Product Description
- Diagnostic Assay - Frontotemporal Degeneration - Product Status
- Diagnostic Assay - Frontotemporal Degeneration - Product Description
- Diagnostic Assay - Parkinson's Disease - Product Status
- Diagnostic Assay - Parkinson's Disease - Product Description
- Diagnostic Assay - Rett Syndrome - Product Status
- Diagnostic Assay - Rett Syndrome - Product Description
- Mdx Test - Brain Aging - Product Status
- Mdx Test - Brain Aging - Product Description
- Mdx Test - MCI-AD Progression - Product Status
- Mdx Test - MCI-AD Progression - Product Description
- Mdx Test - Mild Cognitive Impairment - Product Status
- Mdx Test - Mild Cognitive Impairment - Product Description
- Universal Screening Test - Product Status
- Universal Screening Test - Product Description
- DiamiR LLC, Key Employees
- Glossary
- DiamiR LLC Pipeline Products by Equipment Type
- DiamiR LLC Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abcam Inc
- Biognosys Inc
- Exiqon Diagnostics, Inc.
